TLSA Tiziana Life Sciences (TLSA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001723069
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
14
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · no price filed
What the filings say about TLSA
Insiders, 180 days
+$1.0M net bought
2 buyers
Tiziana Life Sciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Tiziana Life Sciences Ltd insiders bought a net $1.0M of stock across 5 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Aug 4, 2026.
- The trade is 5.0% of the 4,793,684 shares held after it.
- 1 other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Elrifi Ivor bought about $237.6K of TLSA on Aug 5, 2026; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 3, 2026.
- The trade is 1.8% of the 4,556,068 shares held after it.
- 1 other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Elrifi Ivor bought about $81.3K of TLSA on Aug 4, 2026; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 14.9% of the 4,472,261 shares held after it.
- 1 other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Elrifi Ivor bought about $667.0K of TLSA on Aug 3, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 12, 2026.
- The trade is 0.1% of the 44,814,587 shares held after it.
- 1 other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CERRONE GABRIELE M bought about $41.9K of TLSA on Jul 21, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 14 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 0.0% of the 44,772,230 shares held after it.
- No other insider bought within 30 days.
- 14 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CERRONE GABRIELE M bought about $16.6K of TLSA on Jun 12, 2026, the largest insider purchase at the company on our record; 14 funds added in the latest 13F quarter.5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.0M over 180 days
+$985.9K over 90 days · +$58.6K of it by a 10%+ holder
more than 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
14 funds bought in last quarter
below 75% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
4.1% of the float short (float per yahoo 2026-10-26) · 3.2 days to cover · settled 2026-09-30
below 65% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TLSA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-54.2%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TLSA: institutional holders (13F)
13F holdings, latest reported quarter
1,162,000 sh
$1.5M
323,240 sh
$413.7K
125,950 sh
$161.2K
119,238 sh
$152.6K
80,222 sh
$102.7K
Congress trades in TLSA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TLSA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
6 registered trials, 4 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
4 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.0M bought by insiders over 180 days, 14 funds added last quarter. Each figure is a federal filing, dated the day it went public.
TLSA financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2024-12 | 2023-12 | 2022-12 | 2021-12 | |
|---|---|---|---|---|
| Net income | -$11.9M | -$17.7M | -$15.4M | -$23.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
TLSA Stock Sonar score 3/7 axes
Find similar shapesCompareTLSA ranks highest on insider conviction (85th percentile) and risk and compliance (62nd), and lowest on institutional and government (25th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TLSA filings, in plain words
Are Tiziana Life Sciences insiders buying or selling TLSA?
In the 180 days to 2026-10-28, Tiziana Life Sciences insiders were net buyers, a net $1.0M across purchases and sales reported on Form 4, by 2 buyers.
Read the full summary
In the 180 days to 2026-10-28, Tiziana Life Sciences insiders were net buyers of TLSA, a net $1.0M across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
